Inhibition of Human Transitional Cell Carcinoma in Vitro Proliferation by Fluoroquinolone Antibiotics

Wingo, 1995, Cancer statistics, 1995, CA Cancer J. Clin., 45, 8, 10.3322/canjclin.45.1.8 Witjes, 1994, Intravesical therapy in superficial bladder cancer, Urology, 43, 2, 10.1016/0090-4295(94)90211-9 Haalf, 1986, Two course of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder, J. Urol., 136, 820, 10.1016/S0022-5347(17)45091-9 Utz, 1970, The plight of the patient with carcinoma in situ of the bladder, J. Urol., 103, 160, 10.1016/S0022-5347(17)61913-X Lutzeyer, 1982, Prognostic parameters in superficial bladder cancer: an analysis of 315 cases, J. Urol., 127, 250, 10.1016/S0022-5347(17)53725-8 Hudson, 1992, When intravesical measures fail: indications for cystectomy in superficial disease, Urol. Clin. North Am., 19, 601, 10.1016/S0094-0143(21)00427-4 Thrasher, 1992, Complications of intravesical chemotherapy, Urol. Clin. North Am., 19, 529, 10.1016/S0094-0143(21)00419-5 Lamm, 1992, Complications of bacillus Calmette-Guerin immunotherapy, Urol. Clin. North Am., 19, 565, 10.1016/S0094-0143(21)00423-7 Sarosdy, 1992, Phase I trial of oral bropirimine in superficial bladder cancer, J. Urol., 147, 31, 10.1016/S0022-5347(17)37126-4 Zehavi-Willner, 1992, The inhibitory effect of ciprofloxacin on proliferation of a murine bladder carcinoma cell line, J. Antimicrob. Chemother., 29, 323, 10.1093/jac/29.3.323 Peretsman, 1994, In vitro growth inhibition of murine transitional cell carcinoma by fluoroquinolone antibiotics, J. Urol., 151, 517A Campoli-Richards, 1988, Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use, Drugs, 35, 375, 10.2165/00003495-198835040-00003 Hussy, 1986, Effects of 4-quinolones and novobiocin on calf thymus DNA polymerase alpha complex, topoisomerase I and II, and growth of mammalian lymphoblasts, Antimicrob. Agents Chemother., 29, 1073, 10.1128/AAC.29.6.1073 Mosman, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J. Immunol. Methods, 65, 55, 10.1016/0022-1759(83)90303-4 Chen, 1994, DNA topoisomerases: essential enzymes and lethal targets, Annu. Rev. Pharmacol. Toxicol., 34, 191, 10.1146/annurev.pa.34.040194.001203 Husain, 1994, Elevation of topoisomerase I messenger RNA, protein and catalytic activity in human tumors: demonstration of tumor type specificity and implications for cancer chemotherapy, Cancer Res., 54, 539 Onishi, 1993, Topoisomerase inhibitors induce apoptosis in thymocytes, Biochim. Biophys. Acta, 1175, 147, 10.1016/0167-4889(93)90017-J Markovits, 1994, Inhibition of DNA topoisomerases I and II and induction of apoptosis by erbstatin and tyrphostin derivatives, Biochem. Pharmacol., 48, 549, 10.1016/0006-2952(94)90285-2 Hoffken, 1985, Pharmacokinetics of ciprofloxacin after oral and parenteral administration, Antimicrob. Agents Chemother., 27, 375, 10.1128/AAC.27.3.375 Lode, 1987, Pharmacokinetics of ofloxacin after parenteral and oral administration, Antimicrob. Agents Chemother., 31, 1338, 10.1128/AAC.31.9.1338 Yuk, 1991, Bioavailability and pharmacokinetics of ofloxacin in healthy volunteers, Antimicrob. Agents Chemother., 35, 384, 10.1128/AAC.35.2.384 Gonzalez, 1984, Multiple dose pharmacokinetics and safety of ciprofloxacin in normal volunteers, Antimicrob. Agents Chemother., 26, 741, 10.1128/AAC.26.5.741 Lamm, 1992, Long term results of intravesical therapy for superficial bladder cancer, Urol. Clin. North Am., 19, 573, 10.1016/S0094-0143(21)00424-9